clinical trial Archive — Page 7 of 16

The research team includes, left to right, Bruno Scaglioni, PhD; Keith Obstein MD, MPH; James Martin, PhD; Claire Landewee, BS; Simone Calò, PhD; and Pietro Valdastri, PhD. (hoto by Susan Urmy)
October 17, 2023

VISE-affiliated researchers conduct phase 1 trial of novel magnetic endoscope for colonoscopies

A Vanderbilt research team is conducting the first phase 1 clinical trial of a magnetic, flexible endoscope that has the potential to provide a safer alternative to standard colonoscopy, particularly for individuals with inflammatory bowel disease.

October 17, 2023

AI predicts blood clot risk in hospitalized children: VUMC study

An artificial intelligence tool developed at Vanderbilt accurately identified pediatric patients at high risk for blood clots in a clinical trial, with no difference in outcomes compared to a control group.

October 17, 2023

Tirzepatide trial shows additional 21.1% weight loss following intensive lifestyle intervention

A Vanderbilt clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were overweight with weight-related comorbidities, excluding Type 2 diabetes.

Wesley Self, MD, MPH
October 17, 2023

How biostatistics saves lives: the Vanderbilt experience

Biostatisticians at VUMC have played a pivotal role in the redesign of clinical trials that rigorously and rapidly determine the effectiveness of life-saving treatments for acutely ill patients.

October 16, 2023

ICU antibiotics may be safe for kidneys

A Vanderbilt study found that two antibiotics thought to cause kidney failure in ICU patients with a severe bacterial infection, especially when combined with another antibiotic, may be safer for the kidneys than previously reported.

Sharon Kantanie, center, participated in the study of a drug that reduced soft-tissue flare-ups and the prevented new areas of abnormal bone formation. With her are, from left, Emily Shardelow, clinical/translational research coordinator; Sharon’s parents, Mary and Stan Kantanie; Margo Black, MSN, manager of research projects for Metabolic Bone Disorders; and Kathryn Dahir, MD, professor of Endocrinology and Diabetes. (photo by Erin O. Smith)
September 28, 2023

Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva

A Vanderbilt clinical trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva.